ALK and non-small cell lung carcinoma: In treating NSCLC, ROS1, and anaplastic lymphoma kinase fusions and epidermal growth factor receptor and BRAF mutations are targeted, among others, with crizotinib, alectinib, osimertinib, and a combination of dabrafenib and trametinib, respectively.